RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., November 20, 2020, /PRNewswire-AsiaNet/-- RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapyThe Phase 3 study is expected to recruit up to 125 patien...
Authors: LATEST ASIANET NEWS RELEASES